Form 4: Eli Lilly EVP Diogo Rau Reports RSU Vesting and Tax Sale

Eli Lilly's EVP & CIDO, Diogo Rau, reported the vesting of 3,752 restricted stock units and a subsequent sale of shares to cover tax liabilities.

Summary

• Diogo Rau, Executive Vice President and Chief Information and Digital Officer (EVP & CIDO) of Eli Lilly and Company, reported transactions involving the company's common stock.
• On February 1, 2026, Rau acquired 3,752 shares of common stock through the vesting of restricted stock units (RSUs) at a price of $0 per share.
• Concurrently, 1,673.538 shares of common stock were disposed of at a price of $1,037.15 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Rau directly holds 21,797.37 shares of Eli Lilly common stock.
• The restricted stock units represent a contingent right to receive one share of Eli Lilly and Company common stock for each unit.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine executive compensation transaction (RSU vesting and tax-related sale) with no significant positive or negative implications for the company's operational or financial performance.

Positives

• The vesting of restricted stock units indicates continued executive compensation and alignment of management interests with shareholder value over the long term.

Negatives

• A portion of the vested shares (1,673.538 shares) was sold to cover tax liabilities, resulting in a reduction of the executive's direct beneficial ownership.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax-related sales are standard executive compensation practices in the pharmaceutical industry, reflecting a pre-planned event rather than a discretionary investment decision.

Comparison to Industry Standards

• StockSavvy.ai observes that the mechanism of RSU vesting followed by a 'sell-to-cover' transaction for tax purposes is a common practice across large-cap pharmaceutical companies like Pfizer, Merck, and Johnson & Johnson, aligning with typical executive equity compensation structures.

Related Party Transactions

• The reported transactions involve an executive (Diogo Rau) of Eli Lilly and Company, which are considered related party dealings in the context of insider reporting.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine executive compensation event, not indicative of a change in company fundamentals or strategy.
• Employees: No direct impact mentioned.

Key Dates

Keywords

Eli Lilly, LLY, Diogo Rau, Form 4, insider transaction, restricted stock units, RSU, stock vesting, executive compensation, common stock